Sunitinib induced fixed drug eruption

Anjali Lalani, Helly Sheth, Harsh Chudasama, Cyril Sajan

Sumandeep Vidyapeeth (Deemed to be University), Vadodara, Gujarat, India

ABSTRACT

Multikinase inhibitors have become first-line agents for the treatment of multiple systemic cancers. Sunitinib is an oral multitargeted tyrosine kinase inhibitor, most commonly used in renal cell carcinoma and gastrointestinal stromal tumor. Fixed drug eruption is a rare cutaneous adverse drug reaction.

Keywords:

Renal cell carcinoma, Multitargeted tyrosine kinase inhibitors, Fixed drug eruption